In 2014, the Global Metabolic Disorder Therapeutics Market size was valued USD XX billion. While in 2015, the market size of metabolic disorder therapeutics was valued over USD XX million. The global metabolic disorder therapeutics market is projected to grow with a CAGR between 4.8% and 5.3% over the forecast period of 2016-2022 and reach USD 200 billion by 2022. Metabolism is a process in which human body generates energy from the food humans eat. The food that humans consume comprises proteins, carbohydrates, and fats. Chemicals in human digestive system break the food parts down into sugars and acids. Metabolic disorders occur when abnormal chemical reactions in human body disturb this process. This is due to enzyme deficiency: as all processes in the body are controlled by enzymes. Any disturbance in the pathways involved in the development and metabolism of carbohydrates, proteins, and fats, leads to metabolic disorder.

Increase in academia-industry collaborations for drug developments is the key factor responsible for the growth of metabolic disorder therapeutics market. Furthermore, growing diabetic population is significantly contributing to the growth of this market. Low compliance, adherence rate for metabolic disorder therapies and availability of alternative treatment option are the major challenges faced by the players operating in this market. The global metabolic disorder therapeutics market is anticipated to present several opportunities of growth of market size over the forecast period due to strategic collaborations and acquisition and increased R & D investment.

Segments Covered.

The report segments the metabolic disorder therapeutics market by types of disease and by region. Market segmentation based on types of disease includes diabetes, obesity, hypercholesterolemia and lysosomal storage disease. Among segments given above, diabetes drug segment was the leading segment and accounted for highest market share over 64% globally in 2015. The increasing diabetic population across the globe is one of the significant factors propelling the growth of this segment.

Geographic Coverage and Analysis:

The report provides regional analysis covering geographies such as North America, Europe, Asia Pacific, and Rest of the World (RoW). North America was the largest market for metabolic disorder and likely to continue its dominance with a majority market shares globally over the period of 2014 to 2015. The US was the major contributor in the region, as half of the adult population in the country is suffering from diabetes over past couple of years. Following North America, Asia Pacific accounted to be the most prominent region for metabolic disorder over the forecast period. Healthcare reforms across the region and rising diabetic population especially in India are anticipated to boost the growth in the Asia – Pacific market.

Companies Profiled:

The companies covered in the report include

Novo Nordisk
Sanofi
Merck
AstraZeneca
Eli Lily
AbbVie
Actelion Pharmaceuticals
Amicus Therapeutics
Arena Pharmaceuticals
Astellas Pharma
Biocon
Biospherics
Boehringer Ingelheim
CKD Bio
Concord Biotech
ConjuChem
CureDm
CymaBay Therapeutics
Daewoong
Daiichi Sankyo
Dance Biopharm
DiaMedica